View Financial HealthPreveCeutical Medical 配当と自社株買い配当金 基準チェック /06PreveCeutical Medical配当金を支払った記録がありません。主要情報n/a配当利回り-19.4%バイバック利回り総株主利回り-19.4%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Apr 23PreveCeutical Medical Inc. announced that it expects to receive CAD 1 million in fundingPreveceutical Medical Inc announced a non-brokered private placement of up to 40,000,000 units at an issue price of CAD 0.025 per unit for gross proceeds of CAD 1,000,000 on April 22, 2026. Each unit consists of one common share of the company and one-half of one share purchase warrant. Each warrant entitles the holder thereof to purchase an additional share at an exercise price of CAD 0.05 per warrant share for a period of two years from the closing of the offering. Finders' fees may be paid in connection with the offering. All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after the closing. Completion of the offering remains subject to certain conditions, including, without limitation, confirmation of no objection from the CSE.お知らせ • Aug 06PreveCeutical Medical Inc. announced that it expects to receive CAD 1 million in fundingPreveCeutical Medical Inc. announced a non-brokered private placement of up to 25,000,000 units at a price of CAD 0.04 per unit for gross proceeds of up to CAD 1,000,000 on August 5, 2025. Each unit consists of one common share and one-half of one share purchase warrant. Each warrant entitles the holder thereof to purchase an additional share at an exercise price of CAD 0.06 per warrant share for a period of two years from the closing of the offering. Finders' fees may be paid in connection with the offering. All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after the closing. Completion of the offering remains subject to certain conditions, including, without limitation, confirmation of no objection from the Canadian Securities Exchange.お知らせ • Jun 17PreveCeutical Medical Inc., Annual General Meeting, Aug 15, 2025PreveCeutical Medical Inc., Annual General Meeting, Aug 15, 2025.お知らせ • Jun 12PreveCeutical Medical Inc. announced that it expects to receive CAD 0.75 million in fundingPreveceutical Medical Inc. announced a non-brokered private placement of up to 15,000,000 units at an issue price of CAD 0.05 per unit for gross proceeds of CAD 750,000 on June 11, 2025. Each unit consists of one common share of the company and one-half of one share purchase warrant. Each warrant entitles the holder thereof to purchase an additional share at an exercise price of CAD 0.08 for a period of 24 months from the closing of the offering. Finders' fees may be paid. All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after the closing. Completion of the offering remains subject to certain conditions, including, without limitation, confirmation of no objection from the CSE.お知らせ • May 23PreveCeutical Medical Inc. announced that it has received CAD 0.748383 million in fundingOn May 22, 2025, the PreveCeutical Medical Inc. closed the transaction by raising final tranche of CAD 158,382. In connection with the this tranche, the Company paid finders fees to an eligible finder comprised of CAD 12,670.56 in cash and issued 422,352 Finder’s Warrant. The Finder’s Warrant are exercisable into one additional Share at an exercise price of CAD 0.05 per share for 24 months from the closing of final tranche subject to the Acceleration Right. All securities issued in relation to the final tranche are subject to a hold period expiring four months and one day after closing in accordance with applicable securities laws.お知らせ • Sep 20PreveCeutical Medical Inc. and Endosane Pharmaceuticals GmbH Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD and Pharmacologically Relevant Doses Following Intranasal CBD ApplicationPreveCeutical Medical Inc. announced that Endosane Pharmaceuticals GmbH will proceed with its research initiative focused on preclinical studies to evaluate the brain delivery characteristics of sol-gel technology and whether pharmacologically relevant concentrations of CBD can be achieved with this technology. The company's commitment to advancing medical research is demonstrated through its comprehensive research proposal for a first preclinical study in rats. The primary objectives of this study include: Investigating the potential of sol-gel technology for rapid delivery of CBD to the brain. This includes assessing the amounts achieved, regional distribution, and time course of CBD uptake in the brain. Objective 2: Demonstrating the pharmacological relevance of brain CBD concentrations following intranasal application. Study Design: The research will be conducted through a series of well-structured experiments: Experiment 1: Rats will be administered up to three doses of CBD in sol-gel form via nasal spray. Evaluation will be carried out at six different time points. Brain regions such as the olfactory bulb, prefrontal cortex, parietal cortex, pons, and cerebellum will be assessed, and concentrations of CBD and its metabolites will be quantified using a validated LC-MS/MS assay. Experiment 2: A separate group of rats will receive intranasal CBD administration. Cerebrospinal fluid (CSF) and cardiac blood samples will be collected at specific time points based on the findings from Experiment 1. CBD and metabolite concentrations will be measured using validated LC-MS/MS assays. Experiment 3: Building upon the outcomes of Experiment 1, the study will assess intranasal CBD doses that yield significant brain exposure in rat models of anxiety and chronic pain. These are two conditions in which CBD has already demonstrated preclinical efficacy. Collaborative Efforts: Endosane is collaborating closely with the Brain and Mind Centre of the University of Sydney. A significant breakthrough in this partnership has been the identification of anandamide as a potential blood surrogate marker for CBD's brain activity. The research team has also examined the temporal changes in serum. PreveCeutical and Endosane dedication to research in the field of CBD delivery and pharmacology underscores its commitment to advancing medical knowledgeand improving patient outcomes. The company remains focused on scientific innovation, working diligently to pave the way for novel treatments and therapies.お知らせ • Jul 25PreveCeutical Medical Inc. Files Cyclic Peptides and Uses Thereof in EU and AustraliaPreveCeutical Medical Inc. announced that it is furthering the progress Cyclic peptides and uses thereof of its patent families. PreveCeutical's patent family based on PCT/AU2021/051545 (P113135.PCT, Cyclic peptides and uses thereof), has now entered the national phase in Europe and Australia. The Australian case has been allocated application no. 2021408143, and the European case has been allocated application no. EP21908152.8. This is in addition to patent applications having recently been filed in the US and Canada. PreveCeutical is prosecuting the patent applications to maximize the scope of protection available in those countries and to ensure that effective and secure patents are obtained as the company continue its clinical process.お知らせ • Jun 29PreveCeutical Medical Inc. Files Two Family Patents of Sol-Gel Cannabinoid Formulation and Antiviral Use & Cyclic Peptides and Uses ThereofPreveCeutical Medical Inc. announced that PreveCeutical is furthering the progress of two of its patent families. The patent family based on PCT/AU2021/051383 (P114915, Sol-gel cannabinoid formulation and antiviral use), has now entered the national phase in Europe and Australia. The Australian case has been allocated application no. 2021384063, and the European case has been allocated application no. EP21893149.1. This is in addition to patent applications having recently been filed in the US and Canada. PreveCeutical's patent family based on PCT/AU2021/051545 (P113135.PCT, Cyclic peptides and uses thereof), has now entered the national phase in the US and Canada. The US case has been allocated the application no. US18/268951, and full filing details in Canada are awaited. PreveCeutical is prosecuting the patent applications to maximize the scope of protection available in those countries and to ensure that effective and secure patents are obtained as the company continue its clinical process. Although PreveCeutical believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate or successful.決済の安定と成長配当データの取得安定した配当: PRVC.Fの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: PRVC.Fの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場PreveCeutical Medical 配当利回り対市場PRVC.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (PRVC.F)n/a市場下位25% (US)1.3%市場トップ25% (US)4.1%業界平均 (Pharmaceuticals)1.9%アナリスト予想 (PRVC.F) (最長3年)n/a注目すべき配当: PRVC.Fは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: PRVC.Fは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: PRVC.Fの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: PRVC.Fが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/23 20:36終値2026/07/23 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PreveCeutical Medical Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 23PreveCeutical Medical Inc. announced that it expects to receive CAD 1 million in fundingPreveceutical Medical Inc announced a non-brokered private placement of up to 40,000,000 units at an issue price of CAD 0.025 per unit for gross proceeds of CAD 1,000,000 on April 22, 2026. Each unit consists of one common share of the company and one-half of one share purchase warrant. Each warrant entitles the holder thereof to purchase an additional share at an exercise price of CAD 0.05 per warrant share for a period of two years from the closing of the offering. Finders' fees may be paid in connection with the offering. All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after the closing. Completion of the offering remains subject to certain conditions, including, without limitation, confirmation of no objection from the CSE.
お知らせ • Aug 06PreveCeutical Medical Inc. announced that it expects to receive CAD 1 million in fundingPreveCeutical Medical Inc. announced a non-brokered private placement of up to 25,000,000 units at a price of CAD 0.04 per unit for gross proceeds of up to CAD 1,000,000 on August 5, 2025. Each unit consists of one common share and one-half of one share purchase warrant. Each warrant entitles the holder thereof to purchase an additional share at an exercise price of CAD 0.06 per warrant share for a period of two years from the closing of the offering. Finders' fees may be paid in connection with the offering. All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after the closing. Completion of the offering remains subject to certain conditions, including, without limitation, confirmation of no objection from the Canadian Securities Exchange.
お知らせ • Jun 17PreveCeutical Medical Inc., Annual General Meeting, Aug 15, 2025PreveCeutical Medical Inc., Annual General Meeting, Aug 15, 2025.
お知らせ • Jun 12PreveCeutical Medical Inc. announced that it expects to receive CAD 0.75 million in fundingPreveceutical Medical Inc. announced a non-brokered private placement of up to 15,000,000 units at an issue price of CAD 0.05 per unit for gross proceeds of CAD 750,000 on June 11, 2025. Each unit consists of one common share of the company and one-half of one share purchase warrant. Each warrant entitles the holder thereof to purchase an additional share at an exercise price of CAD 0.08 for a period of 24 months from the closing of the offering. Finders' fees may be paid. All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after the closing. Completion of the offering remains subject to certain conditions, including, without limitation, confirmation of no objection from the CSE.
お知らせ • May 23PreveCeutical Medical Inc. announced that it has received CAD 0.748383 million in fundingOn May 22, 2025, the PreveCeutical Medical Inc. closed the transaction by raising final tranche of CAD 158,382. In connection with the this tranche, the Company paid finders fees to an eligible finder comprised of CAD 12,670.56 in cash and issued 422,352 Finder’s Warrant. The Finder’s Warrant are exercisable into one additional Share at an exercise price of CAD 0.05 per share for 24 months from the closing of final tranche subject to the Acceleration Right. All securities issued in relation to the final tranche are subject to a hold period expiring four months and one day after closing in accordance with applicable securities laws.
お知らせ • Sep 20PreveCeutical Medical Inc. and Endosane Pharmaceuticals GmbH Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD and Pharmacologically Relevant Doses Following Intranasal CBD ApplicationPreveCeutical Medical Inc. announced that Endosane Pharmaceuticals GmbH will proceed with its research initiative focused on preclinical studies to evaluate the brain delivery characteristics of sol-gel technology and whether pharmacologically relevant concentrations of CBD can be achieved with this technology. The company's commitment to advancing medical research is demonstrated through its comprehensive research proposal for a first preclinical study in rats. The primary objectives of this study include: Investigating the potential of sol-gel technology for rapid delivery of CBD to the brain. This includes assessing the amounts achieved, regional distribution, and time course of CBD uptake in the brain. Objective 2: Demonstrating the pharmacological relevance of brain CBD concentrations following intranasal application. Study Design: The research will be conducted through a series of well-structured experiments: Experiment 1: Rats will be administered up to three doses of CBD in sol-gel form via nasal spray. Evaluation will be carried out at six different time points. Brain regions such as the olfactory bulb, prefrontal cortex, parietal cortex, pons, and cerebellum will be assessed, and concentrations of CBD and its metabolites will be quantified using a validated LC-MS/MS assay. Experiment 2: A separate group of rats will receive intranasal CBD administration. Cerebrospinal fluid (CSF) and cardiac blood samples will be collected at specific time points based on the findings from Experiment 1. CBD and metabolite concentrations will be measured using validated LC-MS/MS assays. Experiment 3: Building upon the outcomes of Experiment 1, the study will assess intranasal CBD doses that yield significant brain exposure in rat models of anxiety and chronic pain. These are two conditions in which CBD has already demonstrated preclinical efficacy. Collaborative Efforts: Endosane is collaborating closely with the Brain and Mind Centre of the University of Sydney. A significant breakthrough in this partnership has been the identification of anandamide as a potential blood surrogate marker for CBD's brain activity. The research team has also examined the temporal changes in serum. PreveCeutical and Endosane dedication to research in the field of CBD delivery and pharmacology underscores its commitment to advancing medical knowledgeand improving patient outcomes. The company remains focused on scientific innovation, working diligently to pave the way for novel treatments and therapies.
お知らせ • Jul 25PreveCeutical Medical Inc. Files Cyclic Peptides and Uses Thereof in EU and AustraliaPreveCeutical Medical Inc. announced that it is furthering the progress Cyclic peptides and uses thereof of its patent families. PreveCeutical's patent family based on PCT/AU2021/051545 (P113135.PCT, Cyclic peptides and uses thereof), has now entered the national phase in Europe and Australia. The Australian case has been allocated application no. 2021408143, and the European case has been allocated application no. EP21908152.8. This is in addition to patent applications having recently been filed in the US and Canada. PreveCeutical is prosecuting the patent applications to maximize the scope of protection available in those countries and to ensure that effective and secure patents are obtained as the company continue its clinical process.
お知らせ • Jun 29PreveCeutical Medical Inc. Files Two Family Patents of Sol-Gel Cannabinoid Formulation and Antiviral Use & Cyclic Peptides and Uses ThereofPreveCeutical Medical Inc. announced that PreveCeutical is furthering the progress of two of its patent families. The patent family based on PCT/AU2021/051383 (P114915, Sol-gel cannabinoid formulation and antiviral use), has now entered the national phase in Europe and Australia. The Australian case has been allocated application no. 2021384063, and the European case has been allocated application no. EP21893149.1. This is in addition to patent applications having recently been filed in the US and Canada. PreveCeutical's patent family based on PCT/AU2021/051545 (P113135.PCT, Cyclic peptides and uses thereof), has now entered the national phase in the US and Canada. The US case has been allocated the application no. US18/268951, and full filing details in Canada are awaited. PreveCeutical is prosecuting the patent applications to maximize the scope of protection available in those countries and to ensure that effective and secure patents are obtained as the company continue its clinical process. Although PreveCeutical believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate or successful.